|
|
Blood, 1 July 2006, Vol. 108, No. 1, pp. 74-80.
Prepublished online as a Blood First Edition Paper on March 14, 2006; DOI 10.1182/blood-2005-10-4004.
 Previous Article | Next Article 
Submitted October 6, 2005
Accepted February 22, 2006
Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group
Richard Aplenc*, Todd A Alonzo, Robert B Gerbing, Franklin O Smith, Soheil Meshinchi, Julie A Ross, John Perentesis, William G Woods, Beverly J Lange, and Stella M Davies
University of Pennsylvania, Philadelphia, PA, USA
University of Southern California, Los Angeles, CA, USA
Children's Oncology Group, Arcadia, CA, USA
University of Cincinnati, Cincinnati, OH, USA
Department of Pediatrics, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
University of Minnesota Cancer Center, Minneapolis, MN, USA
Emory University, Atlanta, GA, USA
* Corresponding author; email: raplenc{at}cceb.med.upenn.edu.
We evaluated differences in outcome by ethnicity among children with acute myeloid leukemia (AML). We analyzed 791 children on CCG-2891 and confirmed positive findings in 850 children in CCG-2961. Both Hispanic and black children treated with chemotherapy in CCG-2891 had significantly inferior overall survival (OS) from study entry, compared with white children (37 ± 9% vs. 48 ± 4%, p = 0.016 and 34 ±10% vs. 48 ± 4%, p = 0.007, respectively). Significantly fewer black children had a family donor. Analyses of CCG-2961 confirmed that black children had a significantly decreased OS compared with white children (45 ± 12% vs 60 ± 4%, p = 0.007). The difference in OS between Hispanic and white children approached statistical significance (51 ± 8% vs. 60 ± 4%, p = 0.065). Only 7.5% of black children on CCG-2961 had an available family donor. In conclusion, Hispanic and black children with AML have worse survival than white children. Access to chemotherapy, differences in supportive care or leukemia phenotype, and reduced compliance are unlikely explanations for this difference, as therapy was given intravenously according to CCG protocols. Fewer black children than expected had an available family marrow donor.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. L. Metzger, S. M. Castellino, M. M. Hudson, S. N. Rai, S. C. Kaste, M. J. Krasin, L. E. Kun, C.-H. Pui, and S. C. Howard
Effect of Race on the Outcome of Pediatric Patients With Hodgkin's Lymphoma
J. Clin. Oncol.,
March 10, 2008;
26(8):
1282 - 1288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J.L. Kaspers and C. M. Zwaan
Pediatric acute myeloid leukemia: towards high-quality cure of all patients
Haematologica,
November 1, 2007;
92(11):
1519 - 1532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Howell, K. C. Ward, H. D. Austin, J. L. Young, and W. G. Woods
Access to Pediatric Cancer Care by Age, Race, and Diagnosis, and Outcomes of Cancer Treatment in Pediatric and Adolescent Patients in the State of Georgia
J. Clin. Oncol.,
October 10, 2007;
25(29):
4610 - 4615.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Meshinchi and R. J. Arceci
Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia
Oncologist,
March 1, 2007;
12(3):
341 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Davies
Pharmacogenetics, Pharmacogenomics and Personalized Medicine: Are We There Yet?
Hematology,
January 1, 2006;
2006(1):
111 - 117.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
